Micafungin Xellia

Micafungin, the active ingredient in Micafungin Xellia, is an echinocandin presented as an injectable solution for intravenous use. It treats serious fungal infections such as invasive candidiasis and Candida esophagitis, and is used for prophylaxis in high‑risk transplant patients.

GNH USA supplies Micafungin Xellia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal that targets invasive Candida infections and related conditions. - Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Candida esophagitis: resolves esophageal infection and associated symptoms. - Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during periods of severe immunosuppression.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Elevated liver enzymes: mild transaminase rise. - Rash: localized skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Hypersensitivity reactions: anaphylaxis or severe skin eruptions. - Renal impairment: acute kidney injury in susceptible patients. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Infusion-related reactions: hypotension or bronchospasm.

Before initiating Micafungin therapy, clinicians should assess patient-specific risk factors and monitor relevant clinical parameters. - Liver function: obtain baseline tests and repeat periodically. - Renal function: evaluate creatinine clearance in patients with kidney disease. - Drug interactions: review concomitant medications for potential CYP or transporter effects. - Pregnancy and lactation: avoid use unless benefits outweigh unknown risks. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other agents that affect hepatic metabolism or share similar toxicity profiles.

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure may raise toxicity risk. - Rifampin: strong inducer may markedly reduce micafungin levels.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may alter liver enzyme activity. - Immunosuppressants (e.g., tacrolimus): monitor trough levels. - Statins: observe for potential additive hepatotoxicity.